Andres J Yarur1, Alexandra Bruss2, Snehal Naik3, Poonam Beniwal-Patel4, Caroline Fox4, Anjali Jain3, Brandon Berens2, Amir Patel4, Ryan Ungaro5, Bayda Bahur3, Marla Dubinsky5, Daniel J Stein4. 1. Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Hub for Collaborative Medicine, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA. ayarur@mcw.edu. 2. Clinical Translational Science Institute, Medical College of Wisconsin, Milwaukee, WI, USA. 3. Prometheus Laboratories Inc, San Diego, CA, USA. 4. Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Hub for Collaborative Medicine, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA. 5. Icahn School of Medicine, Mount Sinai Hospital, New York, NY, USA.
Abstract
BACKGROUND: The aim of this study was to assess the relationship of serum vedolizumab concentrations (SVC) during induction and endoscopic remission in patients with inflammatory bowel diseases (IBD) after 52 weeks of therapy with vedolizumab. We also sought to assess the incidence of antibody to vedolizumab (ATV) formation, the effect of ATV on drug pharmacokinetics and efficacy, and identify variables associated with SVC through the first 30 weeks of treatment. METHODS: This is a prospective cohort study of patients with active IBD initiating standard therapy with vedolizumab. Collected variables included demographics, clinical disease activity, biomarkers, pre-infusion SVC, and ATV measured at weeks 2, 6, 14, 22, and 30. Primary outcome was steroid-free endoscopic remission at week 52. RESULTS: Fifty-five patients were included. Patients that achieved steroid-free endoscopic remission by week 52 had higher SVC at weeks 2, 6, 14, 22, and 30, but only achieved statistical significance at weeks 2 and 6. Only 3 out of the 55 study subjects (5.5%) had detectable ATV through the follow-up. Overall, there were a positive correlation between SVC and serum albumin and a negative correlation with C-reactive protein, fecal calprotectin, and body mass. Vedolizumab concentrations ≥ 23.2 mcg/ml at week 2 were associated with endoscopic remission at week 52 (OR 8.8 [95% CI 2.6-29.7], p < 0.001). CONCLUSIONS: Vedolizumab concentrations during induction were associated with endoscopic remission at week 52. Interventional studies looking into improved efficacy with higher drug exposure are warranted.
BACKGROUND: The aim of this study was to assess the relationship of serum vedolizumab concentrations (SVC) during induction and endoscopic remission in patients with inflammatory bowel diseases (IBD) after 52 weeks of therapy with vedolizumab. We also sought to assess the incidence of antibody to vedolizumab (ATV) formation, the effect of ATV on drug pharmacokinetics and efficacy, and identify variables associated with SVC through the first 30 weeks of treatment. METHODS: This is a prospective cohort study of patients with active IBD initiating standard therapy with vedolizumab. Collected variables included demographics, clinical disease activity, biomarkers, pre-infusion SVC, and ATV measured at weeks 2, 6, 14, 22, and 30. Primary outcome was steroid-free endoscopic remission at week 52. RESULTS: Fifty-five patients were included. Patients that achieved steroid-free endoscopic remission by week 52 had higher SVC at weeks 2, 6, 14, 22, and 30, but only achieved statistical significance at weeks 2 and 6. Only 3 out of the 55 study subjects (5.5%) had detectable ATV through the follow-up. Overall, there were a positive correlation between SVC and serum albumin and a negative correlation with C-reactive protein, fecal calprotectin, and body mass. Vedolizumab concentrations ≥ 23.2 mcg/ml at week 2 were associated with endoscopic remission at week 52 (OR 8.8 [95% CI 2.6-29.7], p < 0.001). CONCLUSIONS:Vedolizumab concentrations during induction were associated with endoscopic remission at week 52. Interventional studies looking into improved efficacy with higher drug exposure are warranted.
Authors: Andres J Yarur; Anjali Jain; Scott I Hauenstein; Maria A Quintero; Jamie S Barkin; Amar R Deshpande; Daniel A Sussman; Sharat Singh; Maria T Abreu Journal: Inflamm Bowel Dis Date: 2016-02 Impact factor: 5.325
Authors: Elana A Maser; Renata Villela; Mark S Silverberg; Gordon R Greenberg Journal: Clin Gastroenterol Hepatol Date: 2006-08-22 Impact factor: 11.382
Authors: Erwin Dreesen; Bram Verstockt; Sumin Bian; Magali de Bruyn; Griet Compernolle; Sophie Tops; Maja Noman; Gert Van Assche; Marc Ferrante; Ann Gils; Séverine Vermeire Journal: Clin Gastroenterol Hepatol Date: 2018-04-25 Impact factor: 11.382
Authors: Nicolas Williet; Gilles Boschetti; Marion Fovet; Thomas Di Bernado; Pierre Claudez; Emilie Del Tedesco; Camille Jarlot; Leslie Rinaldi; Anne Berger; Jean-Marc Phelip; Bernard Flourie; Stéphane Nancey; Stéphane Paul; Xavier Roblin Journal: Clin Gastroenterol Hepatol Date: 2016-11-24 Impact factor: 11.382
Authors: Andres J Yarur; Amar R Deshpande; David M Pechman; Leonardo Tamariz; Maria T Abreu; Daniel A Sussman Journal: Am J Gastroenterol Date: 2011-03-08 Impact factor: 10.864
Authors: Shui-Long Wang; Linda Ohrmund; Scott Hauenstein; Jared Salbato; Rukmini Reddy; Patrick Monk; Steven Lockton; Nicholas Ling; Sharat Singh Journal: J Immunol Methods Date: 2012-06-09 Impact factor: 2.303
Authors: Brian G Feagan; Paul Rutgeerts; Bruce E Sands; Stephen Hanauer; Jean-Frédéric Colombel; William J Sandborn; Gert Van Assche; Jeffrey Axler; Hyo-Jong Kim; Silvio Danese; Irving Fox; Catherine Milch; Serap Sankoh; Tim Wyant; Jing Xu; Asit Parikh Journal: N Engl J Med Date: 2013-08-22 Impact factor: 91.245
Authors: Jurij Hanzel; Erwin Dreesen; Séverine Vermeire; Mark Löwenberg; Frank Hoentjen; Peter Bossuyt; Esmé Clasquin; Filip J Baert; Geert R D'Haens; Ron Mathôt Journal: Inflamm Bowel Dis Date: 2022-05-04 Impact factor: 7.290